Stock Forecast

  FSD Pharma Inc. ( HUGE) Stock. Should you Buy or Sell?    $ 0.92

-0.01 (-0.40 %)

FSD Pharma Inc. Analysis

Updated on 10-09-2022
Symbol HUGE
Price $0.92
Beta 0.947
Volume Avg. $60 thousand
Market Cap $35.06 M
52 Week Range $0.695 - $1.78

FSD Pharma Inc. opened the day at $0.92 which is -0.40 % on yesterday's close. FSD Pharma Inc. has a 52 week high of $1.78 and 52 week low of $0.695, which is a difference of $1.085. We like to see positive, upward trending shares, preferably with momentum. Market capitalization is $35.06 M and total net profit is $0 which means the company is trading at inf times profit to market capitalization. Theoretically, if you were to buy FSD Pharma Inc. for $35.06 M, it would take 15 years to get your money back. FSD Pharma Inc. are in the Drug Manufacturers—Specialty & Generic space which will have a sweet spot and industry standard for net profit multiples.

Price Chart

1 D | All


FSD Pharma Inc. Stock Forecast - Is FSD Pharma Inc. a Buy or Sell?

DCF ScoreStrong Buy
ROE ScoreSell
ROA ScoreNeutral
DE ScoreNeutral
PE ScoreSell
PB ScoreBuy
Overall RecommendationNeutral

Growth and Value

PE Ratio -1.571
Dividend Yiel 0.000
Net Profit Margin 0.000

Valuing FSD Pharma Inc.

Price Book Value Ratio 0.829 Price To Book Ratio 0.829
Price To Sales Ratio 0.000 Price Earnings Ratio -1.571

How liquid is FSD Pharma Inc.

Current Ratio 3.982
Quick Ratio 3.813


Debt Ratio 0.168 Debt Equity Ratio 0.202
Long Term Debt To Capitalization 0.001 Total Debt To Capitalization 0.012

Latest news about FSD Pharma Inc.

FSD Pharma wins FDA and Health Canada approval for IND for Phase 2 Trial of FSD201 for treating inflammatory disorder

FSD Pharma Inc (CSE:HUGE, NASDAQ:HUGE) revealed that it has received a study may proceed letter for its Investigational New Drug (IND) application from the US Food and Drug Administration (FDA) and notice of authorization from Health Canada for its Phase 2 clinical trial of FSD201.   The Toronto-based biopharma firm said the corresponding study protocol is titled "A Randomized, Double-Blind Placebo Controlled Parallel Group Study of Safety and Efficacy of FSD201 in Patients with Chronic Widespread Musculoskeletal Nociplastic Pain Associated with Idiopathic Mast Cell Activation Syndrome.

Date : 06/09/2022

FSD Pharma says Lucid Psycheceuticals subsidiary files patent for novel PEA formulations; presents preclinical toxicology results at international symposium

FSD Pharma (CSE:HUGE, NASDAQ:HUGE) Inc announced that its wholly-owned Lucid Psycheceuticals Inc subsidiary has filed a provisional patent application on novel formulations of palmitoylethanolamide (PEA). The Toronto-based biotechnology company said the new patent application is based on the results of completed preclinical animal toxicology studies and phase 1 clinical trial using FSD201 (ultramicronized PEA), sponsored by FSD Pharma (CSE:HUGE, NASDAQ:HUGE).

Date : 13/07/2022

FSD Pharma submits IND applications to the FDA and Health Canada for Phase 2 clinical trial of FSD-201 to treat an inflammatory disorder

FSD Pharma (CSE:HUGE, NASDAQ:HUGE) Inc has announced that it has submitted Investigation New Drug applications to the US Food and Drug Administration (FDA) and Health Canada for its planned Phase 2 clinical trial of FSD-201 for the treatment of a yet-to-be-disclosed inflammatory disorder. The biotech noted that FSD-201, its proprietary formulation of ultra micronized palmitoylethanolamide, or ultramicronized PEA, was shown to be safe and well tolerated during a Phase 1 clinical trial.

Date : 31/05/2022

FSD Pharma closes $16.4M sale of former cannabis processing plant

FSD Pharma (CSE:HUGE, NASDAQ:HUGE) Inc announced that it has closed the sale of its former cannabis processing facility in Cobourg, Ontario, Canada for gross proceeds of $16.4 million in cash.  The facility became non-essential to FSD Pharma after it decided in early 2020 to exit the cannabis production market to focus on the biotech market, advancing novel drug candidates targeting lucrative areas of unmet medical needs like Muscular Sclerosis, Depression Disorders, and Inflammatory Disorders.

Date : 10/05/2022

FSD Pharma announces expansion of its management and advisory teams

FSD Pharma (CSE:HUGE, NASDAQ:HUGE) Inc. announced that it is expanding its management and advisory teams.

Date : 06/04/2022

About FSD Pharma Inc.

CEO : Dr. Raza Bokhari
Sector : Healthcare
Industry : Drug Manufacturers—Specialty & Generic

Website :

Exchange : NASDAQ Capital Market

Description :

FSD Pharma Inc., through its subsidiaries, operates as a pharmaceutical research and development company. Its lead candidate includes FSD-201 that is in the Phase II clinical trial to treat COVID-19 disease. The company also focuses on Lucid-PSYCH, a psychoactive molecule identified for the potential treatment of neuropsychiatric disorders, such as depressive disorder; and Lucid-MS, a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. FSD Pharma Inc. was founded in 1998 and is headquartered in Toronto, Canada.

My Newsletter

Sign Up For Updates & Newsletters